Masaki Okamoto

Kurume, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 132 publications

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Journal: Respirology (Carlton, Vic.)

Published: February 04, 2026

Association of the lower-lobe volume ratio on three-dimensional computed tomography with disease progression in idiopathic pulmonary fibrosis.

Association of the lower-lobe volume ratio on three-dimensional computed tomography with disease progression in idiopathic pulmonary fibrosis.

Journal: Respiratory investigation

Published: January 27, 2026

Response to Letter to the Editor: Efficacy and Safety of Nintedanib in Japanese Patients With Early-Stage Idiopathic Pulmonary Fibrosis: A One-Year Interim Analysis From a Multicenter Observational Study in Kyushu and Okinawa, Japan.

Response to Letter to the Editor: Efficacy and Safety of Nintedanib in Japanese Patients With Early-Stage Idiopathic Pulmonary Fibrosis: A One-Year Interim Analysis From a Multicenter Observational Study in Kyushu and Okinawa, Japan.

Journal: Clinical therapeutics

Published: October 09, 2025

Three-dimensional computed tomography lung volume analysis associates with the presence of pathological usual interstitial pneumonia in interstitial lung disease.

Three-dimensional computed tomography lung volume analysis associates with the presence of pathological usual interstitial pneumonia in interstitial lung disease.

Journal: Respiratory investigation

Published: August 26, 2025

Volume histogram analysis of whole-lung CT: differentiating usual from nonspecific interstitial pneumonias and predicting prognosis.

Volume histogram analysis of whole-lung CT: differentiating usual from nonspecific interstitial pneumonias and predicting prognosis.

Journal: Japanese journal of radiology

Published: August 22, 2025

Gene variants of interferon induced with helicase C domain 1 in Japanese patients with Dermatomyositis-associated rapidly progressive interstitial lung disease: a genetic association study using whole-exome and Sanger sequencing.

Gene variants of interferon induced with helicase C domain 1 in Japanese patients with Dermatomyositis-associated rapidly progressive interstitial lung disease: a genetic association study using whole-exome and Sanger sequencing.

Journal: Respiratory research

Published: August 02, 2025

CT colonography for assessing visceral obesity: clinical utility beyond colorectal screening.

CT colonography for assessing visceral obesity: clinical utility beyond colorectal screening.

Journal: Abdominal radiology (New York)

Published: July 30, 2025

Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis.

Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis.

Journal: Scientific reports

Published: July 19, 2025

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Journal: American journal of respiratory and critical care medicine

Published: June 13, 2025

Factors Affecting Exercise Tolerance in Patients Who Underwent Video-Assisted Thoracoscopic Surgery for Lung Cancer.

Factors Affecting Exercise Tolerance in Patients Who Underwent Video-Assisted Thoracoscopic Surgery for Lung Cancer.

Journal: Cureus

Published: June 13, 2025

Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial.

Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial.

Journal: Viruses

Published: May 23, 2025

Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicentre, single-arm phase 2 study (TOP-ILD).

Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicentre, single-arm phase 2 study (TOP-ILD).

Journal: ERJ open research

Published: May 22, 2025

Showing 1-12 of 132

Last Updated: 09/26/2026